WO2019166572A1 - Système pharmaceutique pour l'administration transdermique d'un inhibiteur de la c1 estérase - Google Patents

Système pharmaceutique pour l'administration transdermique d'un inhibiteur de la c1 estérase Download PDF

Info

Publication number
WO2019166572A1
WO2019166572A1 PCT/EP2019/055030 EP2019055030W WO2019166572A1 WO 2019166572 A1 WO2019166572 A1 WO 2019166572A1 EP 2019055030 W EP2019055030 W EP 2019055030W WO 2019166572 A1 WO2019166572 A1 WO 2019166572A1
Authority
WO
WIPO (PCT)
Prior art keywords
esterase inhibitor
pharmaceutical
pharmaceutical system
patch
inhibitor
Prior art date
Application number
PCT/EP2019/055030
Other languages
English (en)
Inventor
Bruno Giannetti
Original Assignee
Pharming Intellectual Property B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Property B.V. filed Critical Pharming Intellectual Property B.V.
Publication of WO2019166572A1 publication Critical patent/WO2019166572A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • the present invention relates to the field of medicine, specifically to a pharmaceutical system for transdermal administration of a pharmacologically active ingredient.
  • C1 inhibitor also known as C1 esterase inhibitor
  • C1 esterase inhibitor is a well-known and identified substance.
  • C1 inhibitor belongs to the superfamily of serine proteinase inhibitors and is the only inhibitor of Clr and Cls of the complement system and is the major inhibitor of factor XI la and kallikrein of the contact system.
  • C1 inhibitor inhibits also other serine proteases of the coagulation and fibrinolytic systems like factor XI, tissue type plasminogen activator and plasmin (Schapira M. et al. 1985, Complement 2:1 11 ; Davis A.E. 1988, Ann. Rev. Immunol. 6:595).
  • C1 inhibitor is encoded by a single gene on chromosome 1 1 and consists of 8 exons and 7 introns. The entire genomic sequence is known and codes for a protein of 500 amino acids, including a 22-amino acid signal sequence (Carter P. et al. 1988, Euro. J. Biochem. 173; 163).
  • Plasma C1 inhibitor is a glycoprotein of approximately105 kDa and is heavily glycosylated.
  • Human C1 esterase inhibitor is inter alia used for the treatment of hereditary angioedema (HAE) and for treatment and prevention of ischemia-reperfusion injury.
  • Pharmaceutical grade human C1 esterase inhibitor can be derived from human plasma or can be produced recombinantly in tissue culture cells (such as Chinese Hamster Ovarian (CHO) cells) or in transgenic animals (such as transgenic rabbits).
  • C1 inhibitor is usually administered intravenously and, more recently, subcutaneously (see, e.g., WO2014145519).
  • Transdermal delivery would represent an attractive alternative to intravenous or subcutaneous delivery of C1 inhibitor, as it may enhance effectivity.
  • it is a challenge to deliver a composition comprising the C1 esterase inhibitor via the transdermal route since the typical doses of 25, 50 or 100U per kg bodyweight may require over 10ml of composition to be administered. Accordingly, there is a need for an improved transdermal delivery system of C1 esterase inhibitor.
  • the invention provides for a pharmaceutical system for transdermal administration of the pharmacologically active compound C1 esterase inhibitor, comprising a surface layer and a C1 esterase inhibitor.
  • the invention further provides for the use of a C1 esterase inhibitor as described herein for the manufacture of a pharmaceutical system according to the invention.
  • the invention further provides for a method of treatment of a subject suffering from or susceptible to a condition related to acute or chronic C1 esterase inhibitor deficiency, comprising administration of a pharmaceutical system according to the invention to the subject.
  • the invention provides for a pharmaceutical system for transdermal administration of a pharmacologically active compound having the effect of a C1 esterase inhibitor, comprising a surface layer and the pharmacologically active compound having the effect of a C1 esterase inhibitor, such as a C1 esterase inhibitor.
  • the pharmaceutical system for transdermal administration is herein interchangeably referred to as the pharmaceutical system according to the invention which is a system to provide transdermal delivery of the C1 esterase inhibitor to a subject.
  • the pharmaceutical system according to the invention preferably comprises the pharmacologically active compound having the effect of a C1 esterase inhibitor.
  • the pharmacologically active compound having the effect of a C1 esterase inhibitor is herein interchangeably referred to as the C1 (esterase) inhibitor according to the invention for purpose of conciseness; in the claims C1 esterase inhibitor means C1 esterase inhibitor.
  • a pharmaceutical system according to the invention may be a pharmaceutical patch for transdermal administration which is herein interchangeably referred to as the pharmaceutical patch according to the invention and which is a system for placement on the skin of a subject to provide transdermal delivery of the C1 esterase inhibitor to the subject.
  • a pharmaceutical system according to the invention may be an applicator device comprising a reservoir with C1 esterase inhibitor.
  • the pharmacologically active compound having the effect of a C1 esterase inhibitor can be a C1 esterase inhibitor, an antibody to C1 esterase, an antibody to Kallikrein, a Kallikrein B1 or B2 receptor blocker or an antibody to F XII.
  • a preferred pharmacologically active compound is a C1 esterase inhibitor.
  • the pharmaceutical patch according to the invention will typically be located on a (re)detachable protective layer from which it can be removed immediately before application to the surface of the subject's skin. Protected this way, it may be stored in a blister pack or a sealed bag.
  • the pharmaceutical patch according to the invention can comprise an adhesive layer and a removable protective layer, wherein the adhesive layer is located between the surface layer and the removable protective layer.
  • the adhesive layer and the protective layer may be any known to the person skilled in the art; they may e.g. be as described in EP2809307, in EP2908873 or in WO2014195352, which are herein incorporated by reference.
  • the C1 esterase inhibitor may be present in the surface layer, in the adhesive layer and/or in a (micro)reservoir. Accordingly, in the pharmaceutical patch according to the invention at least a portion of the C1 esterase inhibitor is contained in the adhesive layer, in the surface layer and/or in a (micro)reservoir within the pharmaceutical patch according to the invention.
  • the pharmaceutical patch according to the invention can further comprise a back layer which is impermeable to the C1 esterase inhibitor.
  • the pharmaceutical patch according to the invention can be of the type where the C1 esterase inhibitor diffuses from the patch into the skin in a passive way, which can be facilitated by helper agents that aid the C1 esterase inhibitor to penetrate the skin, such as, but not limited, to dimethyl sulfoxide (DSMO), salicylate and the agents listed in EP2809307, in EP2908873 and in WO2014195352.
  • the pharmaceutical system according to the invention may further comprise microneedles. In case the pharmaceutical system according to the invention is a patch, the microneedles can be on the surface layer of the patch.
  • the system may have a reservoir system operably-linked to the microneedles and comprising at least part of the C1 esterase inhibitor.
  • the reservoir may have any suitable size to accommodate the required amount of C1 esterase inhibitor; for a patch, it may be a microreservoir.
  • Microneedle systems may comprise distinct applicator devices or may be patches (sometimes also referred to as microneedle arrays); both are known in the art, e.g. from WO2015117938, WO2016162449, WO20161 18459, W02006055795, W02007002521 , WO2013055638, WO2013055641 , W02007002522, WO2012122162 and W02010059605, which are herein incorporated by reference.
  • the pharmaceutical system according to the invention may comprise microneedles that are hollow (such as e.g. in WO2010059605), microneedles that are solid (such as e.g. in WO20161 18459, W02007002522, WO2012122162, W02006055795, W02007002521 , WO2013055638 and WO2013055641 ) and/or microneedles that are dissolving and/or hydrogel forming (such as e.g. in Arya et al, 2017 and Ita et al, which is herein incorporated by reference).
  • the microneedles may be coated with the C1 esterase inhibitor.
  • the C1 esterase inhibitor may be present in the needles, may be present in a (micro)reservoir or both.
  • the C1 esterase inhibitor may be present in the needles, may be present in a (micro)reservoir or both. In the latter option, part of the C1 esterase inhibitor will be present in the dissolving and/or hydrogel forming needles and part of the C1 esterase inhibitor will be present in the (micro)reservoir.
  • the pharmaceutical system according to the invention can be a microneedle patch as defined in WO2015117938 and WO2016162449 or is a microneedle device as defined in WO20161 18459, W02007002522, WO2012122162, W02006055795, W02007002521 , WO2013055638, WO2013055641 and/or W02010059605, comprising the C1 esterase inhibitor according to the invention.
  • the pharmaceutical system according to the invention is a microneedle applicator system (e.g. one according to W02006055795, W02007002521 , WO2013055638, WO2013055641 or W02007002522)
  • the C1 esterase inhibitor can be present in a separate reservoir, which may also be referred as a cartridge, vial or container.
  • the separate reservoir enables to keep the C1 esterase inhibitor separate from the applicator, e.g. the C1 esterase inhibitor reservoir can be kept refrigerated while the applicators can be kept at room temperature.
  • the applicator may be a system that uses separate arrays of microneedles.
  • the separate reservoir comprising the C1 esterase inhibitor may be into in a spring-loaded applicator where relaxation of the spring will push the C1 esterase inhibitor through the microneedles into the skin. All these devices are known to the person skilled in the art and are exemplified in the references herein.
  • the C1 esterase inhibitor When the C1 esterase inhibitor is in lyophilized form, it may be reconstituted by addition of an appropriate amount of an appropriate pharmaceutical grade liquid. In the embodiments of the invention, the reconstitution can be performed shortly before administration.
  • the C1 esterase inhibitor is present in a cartridge together with the appropriate pharmaceutical liquid for reconstitution, wherein the C1 esterase inhibitor and the liquid are separated by a membrane.
  • the membrane is disrupted in a first action, thus allowing mixing of the C1 esterase inhibitor with the pharmaceutical liquid for reconstitution and subsequent reconstitution of the C1 esterase inhibitor.
  • the reconstituted C1 esterase inhibitor is administered to the skin of the subject, e.g. by a spring- loaded applicator as described here above.
  • the pharmaceutical liquid can be an aqueous liquid and optionally a buffered aqueous liquid.
  • the surface layer of the patch can have a surface area of at least about 0.5, about 0.7, about 0.75, about 0.8, about 0.9, about 1 .0, about
  • the surface layer of the patch can have a surface area of about 0.5, about 0.7, about 0.75, about 0.8, about 0.9, about 1 .0, about 1 .1 , about 1 .2, about 1 .3, about 1 .4, about 1 .5, about 2, about 3, about 4, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95 or about 100 cm 2 .
  • the surface layer of the patch can have a surface area of at least 0.5, 0.7, 0.75, 0.8, 0.9, 1 .0,
  • the surface layer of the patch has a surface area of 0.5, 0.7, 0.75, 0.8, 0.9, 1 .0,
  • the pharmaceutical system according to the invention can have a surface area of at least about 0.5, about 0.7, about 0.75, about 0.8, about 0.9, about 1 .0, about 1 .1 , about 1 .2, about 1 .3, about 1.4, about 1 .5, about 2, about 3, about 4, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95 or about 100 cm 2 .
  • such pharmaceutical system is a microneedle system according to the invention.
  • the pharmaceutical system according to the invention can have a surface area of about 0.5, about 0.7, about 0.75, about 0.8, about 0.9, about 1 .0, about 1 .1 , about 1 .2, about 1 .3, about 1.4, about 1 .5, about 2, about 3, about 4, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95 or about 100 cm 2 .
  • such pharmaceutical system is a microneedle system according to the invention.
  • the pharmaceutical system according to the invention can have a surface area of at least 0.5, 0.7, 0.75, 0.8, 0.9, 1.0, 1.1 , 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 cm 2 .
  • such pharmaceutical system is a microneedle system according to the invention.
  • the pharmaceutical system according to the invention can have a surface area of 0.5, 0.7, 0.75, 0.8, 0.9, 1.0, 1.1 , 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 cm 2 .
  • such pharmaceutical system is a microneedle system according to the invention.
  • the pharmaceutical system according to the invention can comprise at least about 25, about 50, about 60, about 75, about 80, about 100, about 120, about 140, about 150, about 160, about 180, about 200, about 210, about 220, about 240, about 250, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000, about 1 100, about 1200, about 1300, about 1400, about 1500, about 1600, about 1700, about
  • 1800 about 1900, about 2000, about 2100, about 2200, about 2300, about 2400, about 2500, about 3000, about 3500, about 4000, about 4500, about 5000, about 5500, about 6000, about
  • the pharmaceutical system according to the invention can comprise about 25, about 50, about 60, about 75, about 80, about 100, about 120, about 140, about 150, about 160, about 180, about 200, about 210, about 220, about 240, about 250, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000, about 1 100, about 1200, about 1300, about 1400, about 1500, about 1600, about 1700, about 1800, about 1900, about 2000, about 2100, about 2200, about 2300, about 2400, about 2500, about
  • the pharmaceutical system according to the invention can comprise at least 25, 50, 60, 75, 80, 100, 120, 140, 150, 160, 180, 200, 210, 220, 240, 250, 300, 400, 500, 600, 700, 800, 900, 100, 1 100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, or at least 8000 units of C1 esterase inhibitor.
  • the pharmaceutical system according to the invention can comprise 25, 50, 60, 75, 80, 100, 120, 140, 150, 160, 180, 200, 210, 220, 240, 250, 300, 400, 500, 600, 700, 800, 900, 1000. 1 100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, or 8000 units of C1 esterase inhibitor.
  • the pharmaceutical system according to the invention can comprise at least about 25, about 50, about 60, about 75, about 80, about 100, about 120, about 140, about 150, about 160, about 180, about 200, about 210, about 220, about 240, or about 250 units of C1 esterase inhibitor/cm 2 .
  • the pharmaceutical system according to the invention can comprise about 25, about 50, about 60, about 75, about 80, about 100, about 120, about 140, about 150, about 160, about 180, about 200, about 210, about 220, about 240, or about 250 units of C1 esterase inhibitor/cm 2 .
  • the pharmaceutical system according to the invention can comprise at least 25, 50, 60, 75, 80, 100, 120, 140, 150, 160, 180, 200, 210, 220, 240, 250 units of C1 esterase inhibitor/cm 2 .
  • the pharmaceutical system according to the invention can comprise 25, 50, 60, 75, 80, 100, 120, 140, 150, 160, 180, 200, 210, 220, 240, 250 units of C1 esterase inhibitor/cm 2 .
  • one unit (U) of C1 esterase inhibitor is the amount of C1 esterase inhibitor present in 1 milliliter of human plasma.
  • One such unit corresponds to approximately 275 microgram plasma- derived or recombinant human C1 esterase inhibitor.
  • the volume of the solution may be at most about 0.5ml, about 1 ml, aboutl .5ml, about 2ml, about 3ml, about 4ml, or at most about 5ml.
  • the volume of the solution is at most 0.5ml, 1 ml, 1.5ml, 2ml, 3ml, 4ml, or at most 5ml.
  • the volume of the solution is about 0.5ml, about 1 ml, about 1 .5ml, about2ml, about 3ml, about 4ml, or about 5ml.
  • the volume of the solution is 0.5ml, 1 ml, 1 .5ml, 2ml, 3ml, 4ml, or 5ml.
  • the amount of C1 esterase inhibitor can be 2100 units in 2 or 3ml.
  • the invention provides for a vial comprising about or exactly 700, 1400 or 2100 units of lyophilized C1 esterase inhibitor.
  • the C1 esterase inhibitor can be the as described in W001/57079, which is herein incorporated by reference.
  • the invention further provides for a vial comprising about or exactly 2100 units of reconstituted C1 esterase inhibitor in 2, 3, 4 or 5ml reconstitution liquid; in one embodiment, the C1 esterase inhibitor is as described in W001/57079.
  • the C1 esterase inhibitor may be any C1 esterase inhibitor of pharmaceutical grade known to the person skilled in the art.
  • the C1 esterase inhibitor can be a plasma-derived C1 esterase inhibitor.
  • the C1 esterase inhibitor can be a recombinant C1 esterase inhibitor.
  • the C1 esterase inhibitor may have an amino acid sequence that is substantially identical to the amino acid sequence of human plasma-derived C1 esterase inhibitor.
  • the recombinant C1 esterase inhibitor may be any recombinant C1 esterase inhibitor known the person skilled in the art. It may be produced recombinantly in microbial cells, such as tissue culture cells.
  • a preferred tissue culture cell is a mammalian tissue culture cell, such as a Chinese Hamster Ovarian (CHO) cell or a human tissue culture cell (see e.g. WO2016/081889, which is herein incorporated by reference).
  • the recombinant C1 esterase inhibitor may be produced in transgenic animals.
  • the recombinant C1 esterase inhibitor can be produced in a transgenic non-human mammal, selected from a mouse, goat, bovine, sheep, porcine or an animal from the order Lagomorpha, such as Leporadae, including a rabbit.
  • the recombinant C1 esterase inhibitor can be produced according to the methods described in W001/57079, which is herein incorporated by reference.
  • the C1 esterase inhibitor may be a modified C1 esterase inhibitor as compared to human plasma-derived C1 esterase inhibitor.
  • the C1 esterase inhibitor may be modified with regards to its amino acid sequence including deletions, elongations, truncations, rearrangements as well as fusions with other natural or synthetic molecules.
  • the C1 esterase inhibitor may be modified to modulate the plasma half-life of the C1 esterase inhibitor.
  • a specific modified C1 esterase inhibitor is conjugated to enhance the plasma half-life.
  • Another specific C1 esterase inhibitor is a conjugated C1 esterase inhibitor according to WO2017/176798, which is herein incorporated by reference, which may be a polysialic acid (PSA)-conjugated C1 esterase inhibitor, or a polyethylene glycol (PEG)-conjugated C1 esterase inhibitor.
  • the modification of the C1 esterase inhibitor may be a modified carbohydrate structure as compared to human plasma-derived C1 esterase inhibitor.
  • a specific modified C1 esterase inhibitor has a reduced level of terminal sialic acid residues as compared to plasma derived C1 esterase inhibitor, wherein said reduced level of terminal sialic acid residues may result in a plasma half-life of less than 6 hours.
  • the C1 esterase inhibitor having a reduced level of terminal sialic acid residues as compared to plasma derived C1 esterase inhibitor may be a C1 esterase inhibitor according to W001/57079, W02004100982 and W02007073186 which are herein incorporated by reference.
  • the C1 esterase inhibitor according to the invention may be present as such in the pharmaceutical system according to the invention or may be comprised in a pharmaceutical composition.
  • the pharmaceutical composition may comprise pharmaceutically accepted excipients and/or may comprise a further pharmaceutically active compound.
  • C1 esterase inhibitor such as an antibody to C1 esterase, an antibody to Kallikrein, a Kallikrein B1 or B2 receptor blocker or antibody to F XII.
  • the invention provides for the use of a C1 inhibitor according to the invention for the manufacture of a pharmaceutical system according to the invention.
  • the pharmaceutical system will be assembled according to a method known to the person skilled in the art (e.g. as described in WO2015117938, WO2016162449, WO2016118459,
  • the C1 esterase inhibitor as defined herein may be comprised into the pharmaceutical system.
  • the features of this aspect of the invention can be the features of the first aspect of the invention.
  • the invention provides for the medical use of the pharmaceutical system according to the invention, including but not limited to methods of treatment comprising administration of the pharmaceutical system, use of the pharmaceutical system for treatment, a pharmaceutical system according to the invention for use as a medicament and use of the pharmaceutical system for the manufacture of a medicament to treat a stated condition.
  • methods of treatment comprising administration of the pharmaceutical system, use of the pharmaceutical system for treatment, a pharmaceutical system according to the invention for use as a medicament and use of the pharmaceutical system for the manufacture of a medicament to treat a stated condition.
  • the features of this aspect of the invention can be the features of the first and second aspect of the invention.
  • the medical use herein may thus interchangeably be formulated as a pharmaceutical system according to the invention for use as a medicament for treatment of a subject for a stated condition but can equally be formulated as a method of treatment of a subject for a stated condition using a pharmaceutical system according to the invention, use of a pharmaceutical system according to the invention in the preparation of a medicament to treat a stated condition in a subject and use of a pharmaceutical system according to the invention for the treatment of a subject for a stated condition.
  • Treatment may be therapeutic and/or prophylactic; when the term“treatment” is used, it can thus also be construed as“prevention” or“delay”.
  • a method of treatment of a subject suffering from or susceptible to a condition related to acute or chronic C1 esterase inhibitor deficiency comprising administration of a pharmaceutical system according to the invention to the subject.
  • the subject in the invention may by an animal subject, such as a mammal including cattle, domestic animals like a dog or a cat, or may be a human subject.
  • the condition related to acute or chronic C1 esterase inhibitor deficiency can be hereditary angioedema (HAE) which can be Type I and II as well as angioedema Type III and IV, which may be chronic or acute.
  • HAE hereditary angioedema
  • Another condition to be treated or prevented may be ischemia-reperfusion injury.
  • the invention provides for a method of treatment of a subject suffering from hereditary angioedema (HAE), which may be chronic or acute, comprising administration of a pharmaceutical system according to the invention.
  • HAE hereditary angioedema
  • the invention provides for a method of treatment (or prevention) of a subject suffering from or at risk of ischemia-reperfusion injury, comprising administration of a pharmaceutical system according to the invention.
  • the pharmaceutical system can be a pharmaceutical patch according to the invention and is fixed to the skin of the subject.
  • some pressure can be applied on the pharmaceutical patch.
  • pressure can be applied to the pharmaceutical patch for a certain time such as, for at least 10%, 20%, 30%, 50%, 60%, 70%, 80%, 90% of the time that the pharmaceutical patch is kept on the subject. In an embodiment, pressure is applied during the entire time that the pharmaceutical patch is kept on the subject.
  • the pharmaceutical patch can be applied to any convenient place on the subject, such as the back, shoulder, nates, buttocks or back of the thigh of the subject, to allow the body weight of the subject to apply pressure to the pharmaceutical patch.
  • the pharmaceutical patch can be kept on the subject for at least about half an hour, about one hour, about two, hours, about three hours, about four hours, about five hours, at least about six hours, at least about eight hours, at least about ten hours, at least about twelve hours.
  • the dose transferred by the patch to the subject can be about 5, about 10, about 15m about 20, about 25, about 50 or about 100 units C1 esterase inhibitor per kg bodyweight. In an embodiment, at least about 25 units per kg bodyweight is transferred. In an embodiment, the dose transferred to the subject is 5, 10, 15, 20, 25, 50 or 100 units C1 esterase inhibitor. In an embodiment, at least 25 units per kg bodyweight is transferred. In an embodiment a total dose of about or exactly 700, 1400 or 2100 units is transferred to the subject.
  • the invention further provides for a method of treatment according to the invention, wherein the pharmaceutical system is a microneedle system according to the invention and wherein the microneedle system discharges the C1 esterase inhibitor load into the skin of the subject.
  • the pharmaceutical system is a microneedle system according to the invention and wherein the microneedle system discharges the C1 esterase inhibitor load into the skin of the subject.
  • about or exactly 5, 10, 15, 20, 25, 50 or 100 units of C1 esterase inhibitor per kg bodyweight or a total dose of about or exactly 2100 units of C1 esterase inhibitor is transferred to the subject.
  • examples of the microneedle system that can be used are described in W02006055795, W02007002521 , WO2013055638, WO2013055641 and/or W02007002522.
  • the verb "to comprise” and its conjugations is used in its nonlimiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded.
  • the verb“to consist” may be replaced by“to consist essentially of” meaning that a product or a composition or a nucleic acid molecule or a peptide or polypeptide of a nucleic acid construct or vector or cell as defined herein may comprise additional component(s) than the ones specifically identified; said additional component(s) not altering the unique characteristic of the invention.
  • reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the elements is present, unless the context clearly requires that there be one and only one of the elements.
  • the indefinite article “a” or “an” thus usually means “at least one”.
  • a pharmaceutical system for transdermal administration of a pharmacologically active compound having the effect of a C1 esterase inhibitor comprising a surface layer and the pharmacologically active compound having the effect of a C1 esterase inhibitor, such as a C1 esterase inhibitor.
  • microneedles in case of a patch, the microneedles are on the surface layer optionally comprising a reservoir system operably linked to the microneedles comprising at least a part of the C1 esterase inhibitor.
  • microneedles are hollow, solid, dissolving and/or hydrogel forming microneedles.
  • the pharmaceutical system comprising at least about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000, about 1 100, about 1200, about 1300, about 1400, about 1500, about 1600, about 1700, about 1800, about 1900, about 2000, about 2100, about 2200, about 2300, about
  • the C1 esterase inhibitor is a recombinant C1 esterase inhibitor, preferably a C1 esterase inhibitor having an amino acid sequence that is substantially identical to the amino acid sequence of human plasma-derived C1 esterase inhibitor.
  • a method of treatment of a subject suffering from or susceptible to a condition related to acute or chronic C1 esterase inhibitor deficiency comprising administration of a pharmaceutical system according to any one of embodiment s 1 to 15 to the subject.
  • a method of treatment according to embodiment 17, wherein the condition related to acute or chronic C1 esterase inhibitor deficiency is hereditary angioedema (HAE).
  • HAE hereditary angioedema
  • a method of treatment according to any one of embodiments 19 to 21 wherein the pharmaceutical patch is kept on the subject for at least about half an hour, about one hour, about two, hours, about three hours, about four hours, about five hours, at least about six hours, at least about eight hours, at least about ten hours, at least about twelve hours.
  • a pharmaceutical patch according to the invention with a surface area of 25 cm 2 comprising 2000 units C1 esterase inhibitor (corresponding to a dose of 25 units per kg bodyweight is administered on the back of the thigh. Subsequently, pressure is applied to the pharmaceutical patch by the subject sitting. Within four hours, a decrease of over 20 mm VAS score is achieved (the visual analog scale (VAS); Reidl MA, Ann Allergy Asthma Immunol 2013, 1 10(4):295-9), demonstrating the effectivity of the pharmaceutical patch according to the invention.
  • VAS visual analog scale
  • Reidl MA Reidl MA, Ann Allergy Asthma Immunol 2013, 1 10(4):295-9
  • a pharmaceutical patch according to the invention with a surface area of 25 cm 2 comprising 4000 units C1 esterase inhibitor (corresponding to a dose of 50 units per kg bodyweight is administered on the back of the thigh. Subsequently, pressure is applied to the pharmaceutical patch by the subject sitting. Within four hours, a decrease of over 20 mm VAS score is achieved (the visual analog scale (VAS); Reidl MA, Ann Allergy Asthma Immunol 2013, 1 10(4):295-9), demonstrating the effectivity of the pharmaceutical patch according to the invention.
  • VAS visual analog scale
  • Reidl MA Reidl MA, Ann Allergy Asthma Immunol 2013, 1 10(4):295-9
  • a dose of 2100 units C1 esterase inhibitor comprised in 3 ml of reconstitution buffer is administered to the subject using a microneedle system according to the invention.
  • VAS visual analog scale
  • Reidl MA Ann Allergy Asthma Immunol 2013, 1 10(4):295-9
  • a dose of 2100 units C1 esterase inhibitor comprised in 3 ml of reconstitution buffer is administered to the subject using a microneedle system according to the invention as defined in W02006055795, W02007002521 , WO2013055638, WO2013055641 and W02007002522.
  • VAS visual analog scale
  • Reidl MA Ann Allergy Asthma Immunol 2013, 1 10(4):295-9
  • compositions according to the invention with a surface area of 25 cm2 comprising 4000 units rhC1 esterase inhibitor (corresponding to a dose of 50 units per kg bodyweight is administered on the back of the thigh twice a week over a period of three months. Subsequent to administration, pressure is applied to the pharmaceutical patch by the subject sitting. During the three months treatment period the incidence of acute HAE attacks is significantly reduced by more than 50% as compared to the period prior to the treatment demonstrating the effectivity of the pharmaceutical patch according to the invention.
  • patients may receive acute treatment for angioedema attacks.
  • Blood samples for immunogenicity will be collected at Screening, prior to the first study drug administration in each treatment period, and at the final follow-up visit.
  • Blood samples for C1 INH concentrations will be collected at Screening, pre-injection and post injection (30 minutes) after the first and last (8th) administration of each treatment period.
  • C1q levels will be evaluated at Screening.
  • Patients who experience angioedema attacks during the study may receive acute treatment consisting of open label treatment with rhC1 INH (50 units/kg up to a maximum of 4200 units, for patients > 84 kg), which may be administered at the study center or administered by the patient or a caregiver in their home following appropriate training.
  • acute treatment consisting of open label treatment with rhC1 INH (50 units/kg up to a maximum of 4200 units, for patients > 84 kg), which may be administered at the study center or administered by the patient or a caregiver in their home following appropriate training.
  • the primary endpoint is the monthly HAE attack rate, defined as the number of HAE attacks during each treatment period normalized by the number of days the patient participated in that period.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne le domaine de la médecine, et plus particulièrement un système pharmaceutique pour l'administration transdermique d'un principe pharmacologiquement actif ayant l'effet d'un inhibiteur de la C1 estérase, tel qu'un inhibiteur de la C1 estérase.
PCT/EP2019/055030 2018-02-28 2019-02-28 Système pharmaceutique pour l'administration transdermique d'un inhibiteur de la c1 estérase WO2019166572A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18159175 2018-02-28
EP18159175.1 2018-02-28

Publications (1)

Publication Number Publication Date
WO2019166572A1 true WO2019166572A1 (fr) 2019-09-06

Family

ID=61526606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/055030 WO2019166572A1 (fr) 2018-02-28 2019-02-28 Système pharmaceutique pour l'administration transdermique d'un inhibiteur de la c1 estérase

Country Status (1)

Country Link
WO (1) WO2019166572A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022073041A3 (fr) * 2020-09-30 2022-06-23 NGGT, Inc. Vecteurs d'expression à double fonction et leurs procédés d'utilisation

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057079A2 (fr) 2000-01-31 2001-08-09 Pharming Intellectual Property B.V. Inhibiteur de c1 produit dans du lait de mammiferes transgeniques
WO2004100982A1 (fr) 2003-05-16 2004-11-25 Pharming Intellectual Property B.V. Inhibiteur de c1 a demi-vie courte pour les traitements transitoires
WO2006055795A1 (fr) 2004-11-18 2006-05-26 3M Innovative Properties Company Applicateur de jeux de micro-aiguilles a profil bas
WO2007002521A2 (fr) 2005-06-27 2007-01-04 3M Innovative Properties Company Dispositif applicateur de matrice de micro-aiguilles et procede d'application d'une telle matrice
WO2007002522A1 (fr) 2005-06-27 2007-01-04 3M Innovative Properties Company Ensemble cartouche a micro-aiguilles et son procede d'application
WO2007073186A2 (fr) 2005-12-21 2007-06-28 Pharming Intellectual Property Bv Utilisation d'un inhibiteur de c1 pour la prevention des lesions d'ischemie-reperfusion
WO2010059605A2 (fr) 2008-11-18 2010-05-27 3M Innovative Properties Company Ensemble de microaiguilles creuses et procédé
WO2012122162A1 (fr) 2011-03-07 2012-09-13 3M Innovative Properties Company Dispositifs et procédés de micro-aiguille
WO2013055638A1 (fr) 2011-10-12 2013-04-18 3M Innovative Properties Company Système de pose d'un ensemble de micro-aiguilles intégrées
WO2013055641A1 (fr) 2011-10-12 2013-04-18 3M Innovative Properties Company Système intégré d'administration d'un réseau de micro-aiguilles
WO2014145519A2 (fr) 2013-03-15 2014-09-18 Viropharma Holdings Limited Compositions de c1.inh et méthodes pour la prévention et le traitement de troubles associés à un déficit en inhibiteur de c1 estérase
EP2809307A1 (fr) 2012-01-31 2014-12-10 Grünenthal GmbH Timbre pharmaceutique pour l'administration transdermique de (1r,4r)-6'-fluoro-n,n-diméthyl-4-phényl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
WO2014195352A1 (fr) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Système d'administration transdermique
WO2014207199A1 (fr) * 2013-06-28 2014-12-31 Csl Behring Gmbh Polythérapie utilisant un inhibiteur du facteur xii et un inhibiteur de c1
WO2015077543A1 (fr) * 2013-11-22 2015-05-28 Viropharma Holdings Limited Méthodes de traitement de rejet médié par les anticorps chez des patients transplantés à l'aide d'un inhibiteur de c1-estérase
WO2015117938A1 (fr) 2014-02-10 2015-08-13 Lts Lohmann Therapie-Systeme Ag Système de micro-aiguilles et son procédé de fabrication
EP2908873A1 (fr) 2013-05-20 2015-08-26 Edixomed Limited Système d'administration transdermique
WO2016081889A1 (fr) 2014-11-21 2016-05-26 Kurt Baekgaard Osther Inhibiteur recombinant de la c1-estérase et utilisation de celui-ci
WO2016118459A1 (fr) 2015-01-21 2016-07-28 3M Innovative Properties Company Agencement de micro-aiguilles et procédé d'utilisation
WO2016160926A1 (fr) * 2015-03-30 2016-10-06 Dyax Corp. Inhibiteurs de la kallicréine plasmatique et utilisations desdits inhibiteurs pour prévenir un accès d'angio-oedème héréditaire
WO2016162449A1 (fr) 2015-04-07 2016-10-13 Lts Lohmann Therapie-Systeme Ag Système à microaiguilles pour l'application de formulations liquides
WO2017087882A1 (fr) * 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Inhibiteur de la c1 estérase humaine recombinante et ses utilisations
WO2017176798A1 (fr) 2016-04-04 2017-10-12 Shire Human Genetic Therapies, Inc. Inhibiteur de c1 estérase conjugué et ses utilisations

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057079A2 (fr) 2000-01-31 2001-08-09 Pharming Intellectual Property B.V. Inhibiteur de c1 produit dans du lait de mammiferes transgeniques
WO2004100982A1 (fr) 2003-05-16 2004-11-25 Pharming Intellectual Property B.V. Inhibiteur de c1 a demi-vie courte pour les traitements transitoires
WO2006055795A1 (fr) 2004-11-18 2006-05-26 3M Innovative Properties Company Applicateur de jeux de micro-aiguilles a profil bas
WO2007002521A2 (fr) 2005-06-27 2007-01-04 3M Innovative Properties Company Dispositif applicateur de matrice de micro-aiguilles et procede d'application d'une telle matrice
WO2007002522A1 (fr) 2005-06-27 2007-01-04 3M Innovative Properties Company Ensemble cartouche a micro-aiguilles et son procede d'application
WO2007073186A2 (fr) 2005-12-21 2007-06-28 Pharming Intellectual Property Bv Utilisation d'un inhibiteur de c1 pour la prevention des lesions d'ischemie-reperfusion
WO2010059605A2 (fr) 2008-11-18 2010-05-27 3M Innovative Properties Company Ensemble de microaiguilles creuses et procédé
WO2012122162A1 (fr) 2011-03-07 2012-09-13 3M Innovative Properties Company Dispositifs et procédés de micro-aiguille
WO2013055638A1 (fr) 2011-10-12 2013-04-18 3M Innovative Properties Company Système de pose d'un ensemble de micro-aiguilles intégrées
WO2013055641A1 (fr) 2011-10-12 2013-04-18 3M Innovative Properties Company Système intégré d'administration d'un réseau de micro-aiguilles
EP2809307A1 (fr) 2012-01-31 2014-12-10 Grünenthal GmbH Timbre pharmaceutique pour l'administration transdermique de (1r,4r)-6'-fluoro-n,n-diméthyl-4-phényl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
WO2014145519A2 (fr) 2013-03-15 2014-09-18 Viropharma Holdings Limited Compositions de c1.inh et méthodes pour la prévention et le traitement de troubles associés à un déficit en inhibiteur de c1 estérase
EP2908873A1 (fr) 2013-05-20 2015-08-26 Edixomed Limited Système d'administration transdermique
WO2014195352A1 (fr) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Système d'administration transdermique
WO2014207199A1 (fr) * 2013-06-28 2014-12-31 Csl Behring Gmbh Polythérapie utilisant un inhibiteur du facteur xii et un inhibiteur de c1
WO2015077543A1 (fr) * 2013-11-22 2015-05-28 Viropharma Holdings Limited Méthodes de traitement de rejet médié par les anticorps chez des patients transplantés à l'aide d'un inhibiteur de c1-estérase
WO2015117938A1 (fr) 2014-02-10 2015-08-13 Lts Lohmann Therapie-Systeme Ag Système de micro-aiguilles et son procédé de fabrication
WO2016081889A1 (fr) 2014-11-21 2016-05-26 Kurt Baekgaard Osther Inhibiteur recombinant de la c1-estérase et utilisation de celui-ci
WO2016118459A1 (fr) 2015-01-21 2016-07-28 3M Innovative Properties Company Agencement de micro-aiguilles et procédé d'utilisation
WO2016160926A1 (fr) * 2015-03-30 2016-10-06 Dyax Corp. Inhibiteurs de la kallicréine plasmatique et utilisations desdits inhibiteurs pour prévenir un accès d'angio-oedème héréditaire
WO2016162449A1 (fr) 2015-04-07 2016-10-13 Lts Lohmann Therapie-Systeme Ag Système à microaiguilles pour l'application de formulations liquides
WO2017087882A1 (fr) * 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Inhibiteur de la c1 estérase humaine recombinante et ses utilisations
WO2017176798A1 (fr) 2016-04-04 2017-10-12 Shire Human Genetic Therapies, Inc. Inhibiteur de c1 estérase conjugué et ses utilisations

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARYA ET AL., BIOMATERILAS, vol. 128, 2017, pages 1 - 7
CARTER P. ET AL., EURO. J. BIOCHEM., vol. 173, 1988, pages 163
DAVIS A.E., ANN. REV. IMMUNOL., vol. 6, 1988, pages 595
ITA, PHARMACEUTICS, vol. 7, 2015, pages 90 - 105
REIDL MA, ANN ALLERGY ASTHMA IMMUNOL, vol. 110, no. 4, 2013, pages 295 - 9
SCHAPIRA M. ET AL., COMPLEMENT, vol. 2, 1985, pages 111

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022073041A3 (fr) * 2020-09-30 2022-06-23 NGGT, Inc. Vecteurs d'expression à double fonction et leurs procédés d'utilisation

Similar Documents

Publication Publication Date Title
TWI234462B (en) Methods for treating pain
TWI284536B (en) Novel use of botulinum in the treatment of parathyroid and calcemia disorders
US9044436B2 (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
ES2555856T3 (es) Tratamiento de neoplasmas con neurotoxina
KR20200143407A (ko) Cgrp를 억제하는데 사용하기 위한 신경독소
ES2251248T3 (es) Uso de anticuerpos contra il-12 para tratar la psoriasis.
JP2015520188A5 (fr)
WO2013136234A1 (fr) Dispositifs d'administration transdermique
BR112016011499A2 (pt) uso de uma composição compreendendo um inibidor da proteína c1-esterase (c1-inh), composição farmacêutica compreendendo o mesmo e seus kits
US20220054595A1 (en) Formulation Including a Combination of beta-Endorphin and Adrenocorticotropic Hormone
CN1997383B (zh) 含水母发光蛋白的组合物及使用它的方法
ES2433915T3 (es) Vacunas de ADN que codifican proteínas de choque térmico
WO2019166572A1 (fr) Système pharmaceutique pour l'administration transdermique d'un inhibiteur de la c1 estérase
Renner et al. Ceruletide-induced acute pancreatitis in the dog and its amelioration by exogenous secretin
ES2449044T3 (es) Procedimiento de administración de fVIII sin dominio B porcino
ES2287161T3 (es) Analogos de trombomodulina para uso en la recuperacion de la lesion de la medula espinal.
WO2016064998A1 (fr) Promotion de régénération épithéliale post-amygdalectomie au moyen du facteur de croissance mimétique du facteur de croissance épidermique se liant à l'héparine
US20180036394A1 (en) Pharmaceutical formulations of c1 esterase inhibitor
US10357533B2 (en) Drug for the effective control of acute and or chronic pain and a method for its administration
Lumry Management and prevention of hereditary angioedema attacks
TW201728338A (zh) 免疫球蛋白ｇ組合物
EP3530279B1 (fr) Composition pharmaceutique pour l'utilisation dans le traitement de dysfonctions sexuelles féminines
Powell The next generation of anti-haemophilia factor, factor VIII
WO2019231860A1 (fr) Procédé de traitement ou de prévention de la mucosite orale associée à une radiothérapie et à une chimiothérapie utilisant un facteur de croissance de type facteur de croissance épidermique se liant à l'héparine (hb-egf) administré par voie locale
WO2023122355A2 (fr) Méthodes de traitement ou de prévention de réactions liées à la perfusion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19706300

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19706300

Country of ref document: EP

Kind code of ref document: A1